CTI(SZ:300012) Changjiang Securities·2025-10-15 06:20Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - The company forecasts a year-on-year increase of 10%-13% in net profit attributable to shareholders for Q3 2025, with a projected net profit of 341-350 million yuan, marking the first time in nine quarters that the growth rate exceeds 10% [2][6][7]. - The company is steadily advancing its strategic mergers and acquisitions and international expansion, which are expected to contribute to performance in Q4 [2][6][13]. Revenue Performance - For the first three quarters of 2025, the company anticipates a net profit of 808-818 million yuan, reflecting a year-on-year growth of 8.26%-9.51% [6]. - Revenue from various business segments includes: - Life Sciences Testing: 1.27 billion yuan, up 1.11% - Industrial Testing: 600 million yuan, up 7.47% - Consumer Testing: 520 million yuan, up 13.15% - Trade Assurance Testing: 430 million yuan, up 13.48% - Medical and Pharmaceutical Testing: 140 million yuan, up 1.30% [7][8]. Profitability - The company achieved a net profit margin of 15.7% in the first half of the year, remaining stable year-on-year, with a gross margin of 49.6%, slightly up by 0.07 percentage points [8]. - The company is focusing on lean management and digital transformation to strengthen its core competitive advantages, with expectations for improved profitability in the medical and semiconductor testing segments [8]. International Expansion - The company has made significant strides in international acquisitions, including the full acquisition of ALS Group's branch in Guangzhou and agreements to acquire stakes in companies in Hong Kong, Vietnam, South Africa, and Greece [13]. - The overseas revenue contribution is approximately 7.30%, showing a year-on-year increase of 20.82% [13]. Financial Forecast - Revenue projections for 2025-2027 are as follows: - 2025: 6.521 billion yuan - 2026: 7.191 billion yuan - 2027: 7.921 billion yuan - Net profit forecasts for the same period are: - 2025: 1.014 billion yuan - 2026: 1.143 billion yuan - 2027: 1.287 billion yuan - Corresponding PE ratios are projected at 22.7x, 20.2x, and 17.9x respectively [13].